Limits...
The clinical significance of HER2 protein amplification/expression in urinary bladder lesion.

Hammam O, Nour HH, Mosaad M, Akl M, Khalil H, Al Ganzory H, Hindawi A - Arab J Urol (2015)

Bottom Line: HER2 expression was statistically significantly higher in patients with malignant lesions than in the other groups, and in high-stage and -grade tumours than in low-stage and -grade tumours.Schistosomal infestation did not affect HER2 expression in patients with transitional cell carcinoma.The treatment of HER2-positive tumours might benefit from novel targeted-treatment protocols.

View Article: PubMed Central - PubMed

Affiliation: Pathology Department, Theodor Bilharz Research Institute, Giza Egypt.

ABSTRACT

Objective: To evaluate HER2 oncoprotein expression by both immunohistochemical (IHC) staining and fluorescence in situ hybridisation (FISH) in different benign and malignant bladder lesions, and the effect of bilharzial infestation on this expression.

Patients and methods: In a prospective controlled study, 72 patients were classified into a control group, and groups with cystitis, urothelial carcinoma, and squamous cell carcinoma (SCC). HER2 was detected using standard IHC staining and FISH in all groups. The correlation of HER2 expression with tumour type, stage and grade in relation to normal urothelium and cystitis was assessed. The effect of schistosomal infestation was evaluated.

Results: HER2 expression was statistically significantly higher in patients with malignant lesions than in the other groups, and in high-stage and -grade tumours than in low-stage and -grade tumours. The use of FISH increased the detection of HER2-positive tumours. Schistosomal infestation did not affect HER2 expression in patients with transitional cell carcinoma.

Conclusion: High-stage and -grade bladder malignancies expressed HER2 much more than did benign lesions. FISH is more sensitive for detecting HER2 expression. The treatment of HER2-positive tumours might benefit from novel targeted-treatment protocols.

No MeSH data available.


Related in: MedlinePlus

HER2 amplification by FISH. (A) Papillary urothelial TCC, negative for HER2 gene amplification. (B) Urothelial TCC, positive for HER2 gene amplification, showing red clusters. (C) Bilharzial SCC, negative for HER2 gene amplification. (D) SCC, positive for HER2 gene amplification, showing >6 red signals per cell. All ×60.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4561918&req=5

f0010: HER2 amplification by FISH. (A) Papillary urothelial TCC, negative for HER2 gene amplification. (B) Urothelial TCC, positive for HER2 gene amplification, showing red clusters. (C) Bilharzial SCC, negative for HER2 gene amplification. (D) SCC, positive for HER2 gene amplification, showing >6 red signals per cell. All ×60.

Mentions: HER2 expression was positive in 33% of TCC (Fig. 2A and B), compared with only 27% positive by IHC staining (P < 0.05), and was similar for SCC (Fig. 2, C and D), with HER2 expression of 37% by IHC staining but 53% by FISH (P < 0.01).


The clinical significance of HER2 protein amplification/expression in urinary bladder lesion.

Hammam O, Nour HH, Mosaad M, Akl M, Khalil H, Al Ganzory H, Hindawi A - Arab J Urol (2015)

HER2 amplification by FISH. (A) Papillary urothelial TCC, negative for HER2 gene amplification. (B) Urothelial TCC, positive for HER2 gene amplification, showing red clusters. (C) Bilharzial SCC, negative for HER2 gene amplification. (D) SCC, positive for HER2 gene amplification, showing >6 red signals per cell. All ×60.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4561918&req=5

f0010: HER2 amplification by FISH. (A) Papillary urothelial TCC, negative for HER2 gene amplification. (B) Urothelial TCC, positive for HER2 gene amplification, showing red clusters. (C) Bilharzial SCC, negative for HER2 gene amplification. (D) SCC, positive for HER2 gene amplification, showing >6 red signals per cell. All ×60.
Mentions: HER2 expression was positive in 33% of TCC (Fig. 2A and B), compared with only 27% positive by IHC staining (P < 0.05), and was similar for SCC (Fig. 2, C and D), with HER2 expression of 37% by IHC staining but 53% by FISH (P < 0.01).

Bottom Line: HER2 expression was statistically significantly higher in patients with malignant lesions than in the other groups, and in high-stage and -grade tumours than in low-stage and -grade tumours.Schistosomal infestation did not affect HER2 expression in patients with transitional cell carcinoma.The treatment of HER2-positive tumours might benefit from novel targeted-treatment protocols.

View Article: PubMed Central - PubMed

Affiliation: Pathology Department, Theodor Bilharz Research Institute, Giza Egypt.

ABSTRACT

Objective: To evaluate HER2 oncoprotein expression by both immunohistochemical (IHC) staining and fluorescence in situ hybridisation (FISH) in different benign and malignant bladder lesions, and the effect of bilharzial infestation on this expression.

Patients and methods: In a prospective controlled study, 72 patients were classified into a control group, and groups with cystitis, urothelial carcinoma, and squamous cell carcinoma (SCC). HER2 was detected using standard IHC staining and FISH in all groups. The correlation of HER2 expression with tumour type, stage and grade in relation to normal urothelium and cystitis was assessed. The effect of schistosomal infestation was evaluated.

Results: HER2 expression was statistically significantly higher in patients with malignant lesions than in the other groups, and in high-stage and -grade tumours than in low-stage and -grade tumours. The use of FISH increased the detection of HER2-positive tumours. Schistosomal infestation did not affect HER2 expression in patients with transitional cell carcinoma.

Conclusion: High-stage and -grade bladder malignancies expressed HER2 much more than did benign lesions. FISH is more sensitive for detecting HER2 expression. The treatment of HER2-positive tumours might benefit from novel targeted-treatment protocols.

No MeSH data available.


Related in: MedlinePlus